Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
   Or select

Or become a subscriber

Q&A: Fundamental Diseases

Anthony Hall from fundamental disease charity Findacure Development talks to IPT about the explosion of interest in treatments for rare conditions which has been driven by legislative incentives, and evaluates the future landscape for Big Pharma.

Anthony Hall, Findacure Development, (September 2013)

Keywords: Fundamental diseases Orphan drug legislation Monogenic

    View full article    |    Back to Industry Insight section

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |